# OnCo record st-johns-wort-interaction (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/st-johns-wort-interaction/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "st-johns-wort-interaction" ;
  schema:name "St John's wort: an interaction to avoid"@en ;
  schema:description "St John's wort is a herbal antidepressant whose active ingredient hyperforin switches on the liver enzyme CYP3A4 and the P-glycoprotein pump, cutting blood levels of irinotecan's active metabolite by 42% and imatinib by about a third. It is contraindicated with most tyrosine kinase, CDK4/6 and PARP inhibitors, and its effect lasts two weeks after stopping."@en ;
  schema:url <https://onco.cc/technologies/st-johns-wort-interaction/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hypericum_perforatum> ;
  schema:citation <https://doi.org/10.1093/jnci/94.16.1247>, <https://www.mskcc.org/cancer-care/integrative-medicine/herbs/st-johns-wort> ;
  onco:status "established" ;
  onco:tag "complementary", "supportive-care", "evidence:harm" ;
  onco:related <https://onco.cc/ideas/idea-moon-supplement-interaction-database/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/dietary-supplements-treatment-interactions/>, <https://onco.cc/technologies/integrative-oncology/>, <https://onco.cc/technologies/psycho-oncology/> ;
  onco:drugs <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/folfiri/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/olaparib/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-misinformation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mathijssen-j-natl-cancer-inst/> .